AptarGroup, Inc.

NYSE:ATR

Medical - Instruments & Supplies

Healthcare
$141.67 +0.55%

+$0.66 today

Market cap
$8.98B
Beta
0.40
P/E (TTM)
20.0
EPS (TTM)
$6.04
Dividend yield
1.57%
52W Low $103.23High $164.28

Volume 0.34M

Average 0.51M

ATR Operating Cash Flow

Cash generated by the company's core business operations during the period.

AptarGroup, Inc.NYSE: ATR

Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Operating cash flow declines year over year

Q2 FY2026 operating cash flow of $103.49M fell 17.8% year over year, behind the -5.3% change in trailing-twelve-month operating cash flow. Sequentially, it fell 12.8% from the prior quarter. Over 3 fiscal years it compounded at +6.0% a year.

Context

  • Operating cash flow amounted to 15.1% of revenue in FY2025, down 2.9 pp from a year earlier.
  • Operating cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -17.8% toward the trailing-twelve-month pace of -5.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$103.49M-12.8% QoQ
Last fiscal yearDec 2025
$570M-11.4% YoY
LTMJun 2026
$583.48M-5.3% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.8%——
1 year-11.4%——
3-year CAGR+6.0%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
570M USD
Year-over-year change
-11.4%
4-year CAGR
+11.9%

Operating Cash Flow vs competitors

How ATR compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -5.3% is the 5th highest of 7, against a peer median of +6.9%.
  • Operating cash flow amounts to 14.8% of revenue for ATR, versus a peer median of 9.9%.
ATR Competitors
Operating Cash Flow for ATR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMCRAmcor plcLTM Jun 2026$2.25B USD+62.0%+19.5%9.6%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$662.2M USD-2.1%+1.4%19.9%
SLGNSilgan Holdings Inc.LTM Jun 2026$640.84M USD+86.3%-0.8%9.6%
SONSonoco Products CompanyLTM Sep 2026$630.43M USD-6.3%+10.7%8.6%
ATRAptarGroup, Inc.LTM Jun 2026$583.48M USD-5.3%+6.0%14.8%
STVNStevanato Group S.p.A.LTM Jun 2026€247.03M EUR-17.8%+38.6%20.2%
TRSTriMas CorporationLTM Mar 2026$88.88M USD+15.9%+17.4%10.2%
Peer median (excluding ATR) —+6.9%+14.0%9.9%

Competitors are the stored peer set for ATR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income243.64M239.56M284.18M374.18M392.79M
Depreciation & Amortization234.85M233.71M248.59M263.78M287.36M
Deferred Income Tax(14.36M)(12.11M)(19.88M)(21.41M)(11.69M)
Stock-Based Compensation38.87M40.94M41.29M47.65M0
Change in Working Capital(169.7M)(45M)5.75M(32.26M)(125.45M)
Accounts Receivables(123.25M)(27.94M)15.43M(18.08M)(73.89M)
Inventory(79.96M)(60.35M)(10.64M)21.9M(10.65M)
Accounts Payables52.31M55.1M14.6M(23.71M)(18.27M)
Other Working Capital(18.79M)(11.8M)(13.64M)(12.38M)(22.64M)
Other Non-Cash Items30.13M21.52M15.31M11.47M26.99M
Operating Cash Flow363.44M478.62M575.24M643.41M570M
Capital Expenditures(307.94M)(315.62M)(318.4M)(294.19M)(270.42M)
Acquisitions (Net)(148.42M)(4.1M)(16.57M)0(55.87M)
Purchases of Investments(7.37M)00(101.3M)(8.66M)
Sales of Investments2.43M2.34M5.6M05.77M
Other Investing Activities4.05M21.74M4.91M(1.23M)3.56M
Investing Cash Flow(457.24M)(295.64M)(324.46M)(396.72M)(330.64M)
Debt Repayment36.95M4.99M(51.55M)(97.46M)388.64M
Common Stock Issued000018.89M
Common Stock Repurchased(78.15M)(92.13M)(47.55M)(68.64M)(365.01M)
Dividends Paid(98.51M)(99.46M)(103.68M)(114.06M)(120.78M)
Other Financing Activities58.19M24.5M31.23M54.81M0
Financing Cash Flow(81.52M)(162.1M)(171.55M)(225.34M)(78.26M)
Effect of Forex Changes(6.73M)(1.07M)2.19M(21.15M)16.98M
Net Change in Cash(182.05M)19.81M81.41M201K178.08M
Free Cash Flow55.51M163M256.84M349.22M299.58M

AptarGroup, Inc.

NYSE:ATR

Intrinsic Alpha fair value

Locked

Current Price

$141.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.